Literature DB >> 22702529

Detection of antileishmanial antibodies in blood sampled from blood bank donors in Istanbul.

Sezen Canim Ates1, Malahat Bagirova, Adil M Allahverdiyev, Serap Yesilkir Baydar, Rabia Cakir Koc, Serhat Elcicek, Emrah Sefik Abamor, Olga Nehir Oztel.   

Abstract

AIMS: According to the WHO, only 5-20% of the total cases of leishmaniasis are symptomatic leishmaniasis; the other cases are identified as asymptomatic leishmaniasis. In recent studies, it has been demonstrated that donor blood plays an important role in the epidemiology of asymptomatic leishmaniasis. However, the number of the studies on this subject is still insufficient. Additionally, donor blood samples obtained from Istanbul, which is the biggest metropolitan area in Turkey, have not been investigated with regard to Leishmania. Moreover, there is no information about the sensitivity of noninvasive serological methods that are used in the detection of leishmaniasis donor blood samples. Accordingly, this study aimed to investigate the presence of antileishmanial antibodies in blood samples obtained from blood bank donors in Istanbul, by using different serologic methods, and to determine the most sensitive detection method. MATERIALS &
METHODS: Blood samples were taken from 188 healthy blood bank donors to the Capa Turkish Red Crescent Blood Bank (Istanbul, Turkey), and the presence of antileishmanial antibodies was measured by indirect immunofluorescent antibody test (IFAT), ELISA, immunochromatographic dipstick rapid test, and western blot (WB).
RESULTS: Antileishmanial antibodies were determined in 12 out of 188 samples by IFAT (6.4%), and six out of these 12 donors were found to be positive at diagnostic titer 1:128 (3.2%). One hundred and eighty eight samples were investigated by ELISA and one (0.5%) of them gave a positive result. None of 188 samples provided a positive result by immunochromatographic test. WB applied to the 12 seroreactive donors showed that three out of 12 donors were positive.
CONCLUSION: In this study, the presence of antileishmanial antibodies in blood samples of blood bank donors from Istanbul has been demonstrated by using feasible and low-cost serological methods. Additionally, in comparison with other simple and low-cost detection methods, WB was used for confirmation. IFAT has a higher sensitivity and therefore may be preferred as a prescreening method in endemic or nonendemic areas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22702529     DOI: 10.2217/fmb.12.46

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  4 in total

1.  A Convenient and Sensitive kDNA-PCR for Screening of Leishmania infantum Latent Infection Among Blood Donors in a Highly Endemic Focus, Northwestern Iran.

Authors:  Shabnam Asfaram; Mahdi Fakhar; Mehdi Mohebali; Hajar Ziaei Hezarjaribi; Ahmad Mardani; Behrooz Ghezelbash; Behnaz Akhoundi; Zabihollah Zarei; Maryam Moazeni
Journal:  Acta Parasitol       Date:  2022-03-16       Impact factor: 1.440

Review 2.  Identification of asymptomatic Leishmania infections: a scoping review.

Authors:  Ana Victoria Ibarra-Meneses; Audrey Corbeil; Victoria Wagner; Chukwuemeka Onwuchekwa; Christopher Fernandez-Prada
Journal:  Parasit Vectors       Date:  2022-01-05       Impact factor: 3.876

Review 3.  The current epidemiology of leishmaniasis in Turkey, Azerbaijan and Georgia and implications for disease emergence in European countries.

Authors:  Yusuf Özbel; Seray Töz; Clara Muñoz; Maria Ortuño; Zarima Jumakanova; Pedro Pérez-Cutillas; Carla Maia; Cláudia Conceição; Gad Baneth; André Pereira; Yves Van der Stede; Céline M Gossner; Eduardo Berriatua
Journal:  Zoonoses Public Health       Date:  2022-05-26       Impact factor: 2.954

4.  Serological survey of Leishmania infection in blood donors in Salvador, Northeastern Brazil.

Authors:  Kiyoshi F Fukutani; Virgínia Figueiredo; Fabiana S Celes; Juqueline R Cristal; Aldina Barral; Manoel Barral-Netto; Camila I de Oliveira
Journal:  BMC Infect Dis       Date:  2014-07-30       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.